Neogen Corporation (NASDAQ:NEOG) Q2 2025 Earnings Conference Call January 10, 2024 8:00 AM ET Company Participants Bill Waelke - Vice President, Investor Relations John Adent - Chief Executive Officer and President David Naemura - Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Subbu Nambi - Guggenheim Securities David Westenberg - Piper Sandler Thomas DeBourcy - Nephron Research Operator Good morning, ladies and gentlemen, and welcome to the Neogen Corporation Second Qu ...

Neogen shares have added about 7.7% since the beginning of the year versus the S&P 500's gain of 0.6%. Neogen (NEOG) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this maker of medical testing kits would post earnings of $0.10 per share when it actually produced earnings of $0.07, delivering a surprise of -30%. Over ...

Exhibit 99.1 Neogen Announces Preliminary 1 Second-Quarter 2025 Results 1 Results presented in this release are preliminary and unaudited estimates based on information currently available to the Company. Such results could differ from the final amounts the Company reports in its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024. The Company assumes no obligation, and does not intend, to update these estimates prior to filing its Form 10-Q. 2 Non-GAAP financial measures; see expla ...

Revenue of $231.3 million. Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share. Adjusted Net Income2 of $24.4 million; $0.11 per diluted share. Adjusted EBITDA2 of $51.4 million. Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the preliminary results of the second quarter ended November 30, 2024."The second quarter reflected steady progress, as we saw improvement across the business compared to ...

LANSING, Mich., Jan. 7, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in two upcoming investor conferences. The Company will participate in the CJS Securities 25th Annual Investor Conference, held virtually on January 14, 2025. John Adent, Neogen's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 15, 2025, at 3:45 PM PT. To access the webcast and presentation materials for ...

In its upcoming report, Neogen (NEOG) is predicted by Wall Street analysts to post quarterly earnings of $0.11 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $226.37 million, representing a year-over-year decrease of 1.4%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.P ...

Neogen's (NEOG) vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.Factors Pulling NEOG Stock DownNeogen’s international business continues to be affected due to currency movements. During the fiscal first quarter, the company faced a foreign currency headwind of 390 basis points. Further, the current macroeconomic environment has been affecting Neogen’s financial operations. ...

LANSING, Mich., Dec. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) will issue its second-quarter earnings release before the opening of the market on Thursday, January 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Q2 FY25 Earnings Ca ...

公司动态 - Neogen公司推出Petrifilm Bacillus cereus Count Plate，为食品安全专业人士提供简单、可靠、高效的测试方法 [1] - Petrifilm Bacillus cereus Count Plate是公司Petrifilm产品线的最新成员 [2] - Neogen在2024财年早些时候推出了Petrifilm Automated Feeder，帮助实验室高效处理微生物测试并满足食品安全标准 [4] - Neogen今年早些时候推出了Megazyme的CelluSmart技术，用于测量生物燃料生产中的纤维素乙醇 [9] - 公司还推出了Neogen Molecular Detection Assay – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST)，这是下一代检测试剂盒的一部分 [10] 财务表现 - Neogen当前市值为26.3亿美元 [5] - Zacks对2025财年收入的共识估计为9.351亿美元，较2024财年增长1.2% [5] - 过去一年，Neogen股价下跌39.7%，而行业增长10.9% [11] 行业前景 - Modor Intelligence报告估计，微生物检测市场在2024年价值56.5亿美元，到2029年将达到87.8亿美元，复合年增长率为9.2% [8] - 微生物检测技术的进步和真菌感染病例的增加推动了市场增长 [8] 产品特点 - Petrifilm Bacillus cereus Count Plate提供全面的测试，涵盖整个sensu lato群，包括B. cytotoxicus，可在20小时内提供易于解释的结果 [6] - 该产品消除了传统琼脂方法的准备工作，同时提供微生物测试的准确性和信心 [6] - 该产品帮助食品安全专业人士增强实验室安全协议 [6] - Petrifilm Bacillus cereus Count Plate延续了40年来的可靠性和高效性传统 [7]

公司核心观点 - Neogen Corporation推出了新的Petrifilm Bacillus cereus Count Plate产品，旨在为食品行业提供更简单、可靠和高效的Bacillus cereus检测方法 [1][2] 产品特点 - 新产品提供全面的Bacillus cereus检测，包括B. cytotoxicus，结果可在20小时内获得 [2] - 该产品为即用型，消除了传统琼脂方法的准备工作，同时提供高精度的微生物检测 [3] 公司领导观点 - Neogen的总裁兼CEO John Adent表示，Bacillus cereus是食品行业中的持续威胁，新产品的推出延续了Petrifilm Plates 40年来的可靠性和效率，帮助食品行业专业人士应对关键需求 [4] 公司背景 - Neogen Corporation致力于通过科学和技术推动全球食品安全、动物健康和宠物健康市场的发展，产品覆盖140多个国家 [5]